TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	10.33	2.82	21.05	13.54	10.14
Revenue Growth (YoY)	266.65%	-86.62%	55.52%	33.47%	834.65%
Gross Profit	10.33	2.82	21.05	13.54	10.14
Selling, General & Admin	63.98	60.57	26.35	20.35	13.83
Research & Development	228.3	214.7	88.15	59.82	44.95
Total Operating Expenses	292.28	275.27	114.51	80.17	58.78
Operating Income	-135.81	-134.82	-93.46	-66.64	-48.64
Interest Income	8.82	12.07	8	1.59	0.02
Interest Expense	-2.77	-3.65	-3.76	-1.18	-
Other Non-Operating Income (Expense)	-	-1.09	-	-	-
Total Non-Operating Income (Expense)	6.05	7.32	4.24	0.42	0.02
Pretax Income	-129.77	-127.5	-89.22	-66.22	-48.63
Net Income	-129.77	-127.5	-89.22	-66.22	-48.63
Net Income to Common	-129.77	-127.5	-89.22	-66.22	-48.63
Shares Outstanding (Basic)	130	112	66	24	12
Shares Outstanding (Diluted)	130	112	66	24	12
Shares Change (YoY)	15.88%	70.72%	172.78%	106.20%	1173.20%
EPS (Basic)	-1.00	-1.14	-1.36	-2.75	-4.17
EPS (Diluted)	-1.00	-1.14	-1.36	-2.75	-4.17
Shares Outstanding	56.9	56.59	47.83	24.23	23.91
Free Cash Flow	-139.73	-114.65	-64.5	-70.73	-58.62
Free Cash Flow Per Share	-1.08	-1.02	-0.98	-2.94	-5.03
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1315.38%	-4787.68%	-444.00%	-492.32%	-479.65%
Profit Margin	-1256.81%	-4527.66%	-423.86%	-489.26%	-479.49%
FCF Margin	-1353.28%	-4071.27%	-306.45%	-522.56%	-578.03%
EBITDA	-132.95	-130.71	-88.1	-61.5	-45.31
EBITDA Margin	-1287.62%	-4641.80%	-418.53%	-454.37%	-446.83%
EBIT	-135.81	-134.82	-93.46	-66.64	-48.64
EBIT Margin	-1315.38%	-4787.68%	-444.00%	-492.32%	-479.65%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q